Form 4: Astria Therapeutics Director Hugh Cole Granted 26,550 Stock Options

Astria Therapeutics, Inc. director Hugh M. Cole was granted 26,550 stock options with an exercise price of $5.79, vesting on the one-year anniversary of the grant date.

Summary

• Hugh M. Cole, a Director of Astria Therapeutics, Inc. (ATXS), was granted 26,550 stock options.
• The options have an exercise price of $5.79 per share.
• The grant date for these options was June 11, 2025.
• The options will vest in their entirety on June 11, 2026, which is the one-year anniversary of the grant date, contingent on Mr. Cole's continued service as a director.
• The expiration date for these options is June 10, 2035.

Sentiment

Score: 7

Explanation: The document reports a standard and expected equity grant to a director, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative surprises or adverse events reported.

Positives

• The grant of stock options to a director aligns their interests with shareholders, providing an incentive for long-term company performance.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• No specific negative information is contained within this Form 4 filing.

Risks

• The value of the stock options is subject to the future performance of Astria Therapeutics' stock price, and there is no guarantee that the options will be in-the-money at vesting or exercise.

Future Outlook

The stock options granted to Director Hugh M. Cole are set to vest on June 11, 2026, contingent upon his continued service, providing a long-term incentive tied to the company's future performance.

Industry Context

Stock option grants to directors are a common form of executive and board compensation in the biotechnology and pharmaceutical industries, aiming to align the interests of leadership with long-term shareholder value creation. This practice is standard across publicly traded companies, particularly those in growth-oriented sectors like biopharma, where long-term incentives are crucial for retaining talent and driving innovation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, including those in the biotechnology sector like Astria Therapeutics. Companies such as Biogen (BIIB), Moderna (MRNA), and Vertex Pharmaceuticals (VRTX) frequently utilize similar equity-based compensation to incentivize their board members and executives.
• The vesting schedule of one year is common for director grants, ensuring continued commitment. The exercise price being at market value on the grant date (implied by a typical option grant) is also standard practice.
• The total number of options granted (26,550) would need to be assessed against the company's overall compensation philosophy and peer group benchmarks to determine if it is within typical ranges for a director at a company of Astria's size and stage, but without that context, it appears to be a routine grant.

Related Party Transactions

• The grant of stock options to Hugh M. Cole, a director of Astria Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an individual in a position of influence.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options' value is tied to the company's stock performance. It could be seen as a positive signal of long-term commitment from the board.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grant provides an incentive for the director to contribute to the company's long-term success.

Next Steps

• The granted stock options will vest on June 11, 2026, subject to Hugh M. Cole's continued service as a director.
• Hugh M. Cole will have the right to exercise these options at $5.79 per share until June 10, 2035, assuming they are vested.

Key Dates

Recommendation

Keywords

Astria Therapeutics, ATXS, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Executive Compensation, SEC Filing